| dc.contributor.author | Setyawan, Yuswanto | |
| dc.date.accessioned | 2018-01-09T08:51:01Z | |
| dc.date.available | 2018-01-09T08:51:01Z | |
| dc.date.issued | 2017-07 | |
| dc.identifier.issn | 2337-5949 | |
| dc.identifier.uri | https://dspace.uc.ac.id/handle/123456789/1161 | |
| dc.description.abstract | It is estimated that there are two billions people ever infected by hepatitis B virus (HBV) and there are around 350 milllions people suffering from chronic hepatitis B; 20-25% of them are going to develop chronic liver diorders and hepatocellular carcinoma (HCC). Development in vaccination programs and therapy of hepatitis B infection might trigger the genom mutation in part of viral adaptation to stress (mutant HBV). The characteristic of mutant HBV cases is negative results of anti-HBs and HBsAg, meanwhile other infection markers showed the occurence of HBV infection. Antigenic determinant mostly used to detect this infection is determinant “a” of HbsAg located in the position of 124-127. Changes in that location will disturb detection of HbsAg caused by decreased reactivity against several comercial kits, therefore, the sensitivity will decrease and be undected. Mutant HBV causes difficulty in patient detection and evaluation of blood donor. Besides that, mutation will influence the result of vaccination or therapy due to uneffectiveness of several managements. | en_US |
| dc.language.iso | other | en_US |
| dc.publisher | Perhimpunan Ahli Anatomi Indonesia Komisariat Manado | en_US |
| dc.subject | hepatitis B infection, vaccination and therapy, mutant HBV | en_US |
| dc.title | Virus Hepatitis B Mutan | en_US |
| dc.type | Other | en_US |
